Paul Hastings LLP advised Oppenheimer & Co. and Citizens JMP as joint book running managers in connection with INOVIO Pharmaceutical’s underwritten offering. INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases.

Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi and Securities and Capital Markets partner Will Magioncalda led the Paul Hastings team, which also included associate Chris Guerin.

More details on the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.